Veracyte | VCYT - 营业费用



金融业
股票价格
USD
资产
USD 1.49B
现金及等价物
USD 299.52M
销售成本
USD 42.19M
流动资产
USD 574.78M
流动负债
USD 62.74M
债务
USD 39.33M
EBIT
USD 23.96M
EBITDA
USD 43.96M
员工
824
EPS每股收益
USD 0.54
股本和储备
USD 1.39B
销售毛利
USD 108.55M
债务利息支出
USD 2K
利息收入
USD 3.48M
贷款资金
USD 0
市值
USD 3.23B
净收入
USD 25.49M
营业费用
USD 126.36M
营业利润
USD 23.96M
普通股股本
USD 79.79M
PE价格收益
42.77
税前利润
USD 26.52M
销售收入
USD 150.32M
销售和管理费用
USD 55.71M
股票
USD 22.66M
贸易债权人
USD 8.02M
应收帐款人
USD 54.18M


营业费用 更改 日
Agenus USD -199.08M 22.15M 2026-06
Agilent USD 1.43B 2M 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Bruker USD 768.9M 44.3M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Illumina USD 899M 47M 2026-06
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Laboratory Of America USD 3.27B 146.9M 2026-06
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Myriad Genetics USD 212.8M 16.2M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Siemens EUR 17.6B 531M 2026-06
Sonic Healthcare AUD 4.23B 2.14B 2024-12
Thermo Fisher Scientific USD 9.81B 716M 2026-06
Veracyte USD 126.36M 6.37M 2026-06
Waters USD 527M 592M 2026-06